DOMSTAL O

(Omeprazole and Domperidone Capsules I.P.)

1. Generic Name

Omeprazole and Domperidone Capsules I.P.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each hard gelatin capsule contains: Omeprazole I.P. 10mg (as enteric coated pettets) Domperidone maleate I.P. equivalent to Domperidone 10 mg (as pellets) Colours: Yellow oxide of iron, Red Oxide of iron and Titanium dioxide I.P.

Approved colours used in hard gelatin capsule shell.

The excipients used are Hydroxy Propyl Methyl Celu., Magnesium Stearate, Ferric Oxide Yellow, Ferric Oxide Red, Talc, Ethyl Cellulose, Methanol and Methylene Chloride.

3. Dosage form and strength

Dosage form: Capsule

Strength: Domperidone 10 mg; Omeprazole 10 mg

4. Clinical particulars

4.1 Therapeutic indication

For the treatment of Gastroesophageal Reflux Disease (GERD) not responding to omeprazole alone.

4.2 Posology and method of administration

One capsule once daily or as directed by the physician.

4.3 Contraindications

- Hypersensitivity to the active substances, substituted benzimidazoles or to any of the excipients
- Prolactin-releasing pituitary tumour (prolactinoma)
- When stimulation of the gastric motility could be harmful e.g in patients with gastrointestinal haemorrhage, mechanical obstruction or perforation.
- In patients with moderate or severe hepatic impairment

- In patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure
- Co-administration with QT-prolonging drugs, at the exception of apomorphine
- Co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)
- Concomitant administration with nelfinavir

4.4 Special warnings and precautions for use

Domperidone

Cardiovascular effects

Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. Reportedly, during post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors.

Reported, epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death. A higher risk was observed in patients older than 60 years, patients taking higher doses and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.

Domperidone should be used at the lowest effective dose in adults and adolescents 12 years of age and older.

Domperidone is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia. Electrolyte disturbances (hypokalaemia, hyperkalaemia, hyperkalaemi

Treatment with domperidone should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.

Patients should be advised to promptly report any cardiac symptoms.

Use with apomorphine

Domperidone is contraindicated with QT prolonging drugs including apomorphine, unless the benefit of the co-administration with apomorphine outweighs the risks.

Renal impairment

The elimination half-life of domperidone is prolonged in severe renal impairment. For repeated administration, the dosing frequency or dose may need to be reduced.

Omeprazole

In the presence of any alarming symptoms (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present,

malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis.

Co-administration of atazanavir with proton pump inhibitors is not recommended. If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded.

Omeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.

Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with omeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and omeprazole. The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged.

Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like omeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.

For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.

Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Reported observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.

Subacute cutaneous lupus erythematosus (SCLE)

Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping DOMSTAL O. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.

Interference with laboratory tests

Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, omeprazole treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.

Some children with chronic illnesses may require long-term treatment although it is not recommended.

Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and, in hospitalised patients, possibly also Clostridium difficile.

As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.

4.5 Drugs interactions

Domperidone

The main metabolic pathway of domperidone is through CYP3A4. Reported *in vitro* data suggest that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone.

Increased risk of occurrence of QT-interval prolongation, due to pharmacodynamic and/or pharmacokinetic interactions.

Concomitant use of the following substances is contraindicated

QTc prolonging medicinal products

- anti-arrhythmics class IA (e.g., disopyramide, hydroquinidine, quinidine)
- anti-arrhythmics class III (e.g., amiodarone, dofetilide, dronedarone, ibutilide, sotalol)
- certain anti-psychotics (e.g., haloperidol, pimozide, sertindole)
- certain anti-depressants (e.g., citalopram, escitalopram)
- certain antibiotics (e.g., erythromycin, levofloxacin, moxifloxacin, spiramycin)
- certain antifungal agents (e.g., pentamidine)
- certain antimalarial agents (in particular halofantrine, lumefantrine)
- certain gastro-intestinal medicines (e.g., cisapride, dolasetron, prucalopride)
- certain antihistaminics (e.g., mequitazine, mizolastine)
- certain medicines used in cancer (e.g., toremifene, vandetanib, vincamine)
- certain other medicines (e.g., bepridil, diphemanil, methadone)

• apomorphine, unless the benefit of the co-administration outweighs the risks, and only if the recommended precautions for co-administration are strictly fulfilled. Please refer to the apomorphine SmPC.

Potent CYP3A4 inhibitors (regardless of their QT prolonging effects), i.e.:

- protease inhibitors
- systemic azole antifungals
- some macrolides (erythromycin, clarithromycin, telithromycin)

Concomitant use of the following substances is not recommended

Moderate CYP3A4 inhibitors i.e. diltiazem, verapamil and some macrolides

Concomitant use of the following substances requires caution in use

Caution with bradycardia and hypokalaemia-inducing drugs, as well as with the following macrolides involved in QT-interval prolongation: azithromycin and roxithromycin (clarithromycin is contra-indicated as it is a potent CYP3A4 inhibitor).

The above list of substances is representative and not exhaustive.

Reportedly, separate *in vivo* pharmacokinetic/pharmacodynamic interaction studies with oral ketoconazole or oral erythromycin in healthy subjects confirmed a marked inhibition of domperidone's CYP3A4 mediated first pass metabolism by these drugs.

With the combination of oral domperidone 10mg four times daily and ketoconazole 200mg twice daily, a mean QTc prolongation of 9.8 msec was seen over the observation period, with changes at individual time points ranging from 1.2 to 17.5 msec. With the combination of domperidone 10mg four times daily and oral erythromycin 500mg three times daily, mean QTc over the observation period was prolonged by 9.9 msec, with changes at individual time points ranging from 1.6 to 14.3 msec. Both the Cmax and AUC of domperidone at steady state were increased approximately three-fold in each of these interaction studies. In these studies domperidone monotherapy at 10mg given orally four times daily resulted in increases in mean QTc of 1.6 msec (ketoconazole study) and 2.5 msec (erythromycin study), while ketoconazole monotherapy (200mg twice daily) led to increases in QTc of 3.8 and 4.9 msec, respectively, over the observation period.

Omeprazole

Effects of omeprazole on the pharmacokinetics of other active substances

Active substances with pH dependent absorption

The decreased intragastric acidity during treatment with omeprazole might increase or decrease the absorption of active substances with a gastric pH dependent absorption.

Nelfinavir, atazanavir

The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with omeprazole.

Concomitant administration of omeprazole with nelfinavir is contraindicated. Co-administration of omeprazole (40 mg once daily) reduced mean nelfinavir exposure by ca. 40% and the mean exposure of the pharmacologically active metabolite M8 was reduced by ca. 75 –90%. The interaction may also involve CYP2C19 inhibition.

Concomitant administration of omeprazole with atazanavir is not recommended. Concomitant administration of omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a 75% decrease of the atazanavir exposure. Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg once daily) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared to atazanavir 300 mg/ritonavir 100 mg once daily.

<u>Digoxin</u>

Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased

the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported. However, caution should be exercised when omeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should be then be reinforced.

<u>Clopidogrel</u>

Results from reported studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole (80 mg p.o. daily) resulting in a decreased exposure to the active metabolite of clopidogrel by an average of 46% and a decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 16%.

Reportedly, inconsistent data on the clinical implications of a PK/PD interaction of omeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged.

Other active substances

The absorption of posaconazole, erlotinib, ketoconazole and itraconazole is significantly reduced and thus clinical efficacy may be impaired. For posaconazole and erlotinib concomitant use should be avoided.

Active substances metabolised by CYP2C19

Omeprazole is a moderate inhibitor of CYP2C19, the major omeprazole metabolising enzyme. Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be decreased and the systemic exposure to these substances increased. Examples of such drugs are R-warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin.

<u>Cilostazol</u>

Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.

Phenytoin

Monitoring phenytoin plasma concentration is recommended during the first two weeks after initiating omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a further dose adjustment should occur upon ending omeprazole treatment.

Unknown mechanism

Saquinavir

Concomitant administration of omeprazole with saquinavir/ritonavir resulted in increased plasma levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected patients.

Tacrolimus

Concomitant administration of omeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.

Methotrexate

When given together with proton-pump inhibitors, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of omeprazole may need to be considered.

Effects of other active substances on the pharmacokinetics of omeprazole

Inhibitors of CYP2C19 and/or CYP3A4

Since omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased omeprazole serum levels by decreasing omeprazole's rate of metabolism. Concomitant voriconazole treatment resulted in more than doubling of the omeprazole exposure. As high doses of omeprazole have been well-tolerated, adjustment of the omeprazole dose is not generally required. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.

Inducers of CYP2C19 and/or CYP3A4

Active substances known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St John's wort) may lead to decreased omeprazole serum levels by increasing omeprazole's rate of metabolism.

4.6 Use in special populations

Domperidone

Pregnancy

There are limited post-marketing data on the use of domperidone in pregnant women. Reported studies in animals have shown reproductive toxicity at maternally toxic doses. DOMSTAL O should only be used during pregnancy when justified by the anticipated therapeutic benefit.

Breast-feeding

Domperidone is excreted in human milk and breast-fed infants receive less than 0.1 % of the maternal weight-adjusted dose. Occurrence of adverse effects, in particular cardiac effects cannot be excluded after exposure via breast milk. A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from domperidone therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. Caution should be exercised in case of QTc prolongation risk factors in breast-feed infants.

Omeprazole

Pregnancy

Results from three prospective epidemiological studies (more than 1000 exposed outcomes) indicate no adverse effects of omeprazole on pregnancy or on the health of the foetus/newborn child. Omeprazole can be used during pregnancy.

Breast-feeding

Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used.

Fertility

Reported animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.

4.7 Effects on ability to drive and use machines

DOMSTAL O is not likely to affect the ability to drive or use machines. Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machinery.

4.8 Undesirable effects

The following terms and frequencies are applied:

Very common ($\geq 1/10$); common ($\geq 1/100$ to <1/10); uncommon ($\geq 1/1,000$ to <1/100); rare ($\geq 1/10,000$ to <1/1,000); very rare (<1/10,000), Where frequency cannot be estimated from clinical trials data, it is recorded as "Not known".

Domperidone

System Organ Class	Adverse Drug Reaction Frequency		
	Common	Uncommon	Not known
Immune system disorders			Anaphylactic reaction (including anaphylactic shock)
Psychiatric disorders		Loss of libido Anxiety	Agitation Nervousness
Nervous system disorders		Somnolence Headache	Convulsion Extrapyramidal disorder
Eye disorders			Oculogyric crisis
Cardiac disorders (see section 4.4)			Ventricular arrhythmias Sudden cardiac death QTc prolongation Torsade de Pointes
Gastrointestinal disorders	Dry mouth	Diarrhoea	
Skin and subcutaneous tissue		Rash	Urticaria

System Organ Class	Adverse Drug Reaction Frequency		
	Common	Uncommon	Not known
disorder		Pruritus	Angioedema
Renal and urinary disorders			Urinary retention
Reproductive system and breast disorders		Galactorrhoea Breast pain Breast tenderness	Gynaecomastia Amenorrhoea
General disorders and administration site conditions		Asthenia	
Investigations			Liver function test abnormal Blood prolactin increased

In reported studies where domperidone was used at higher dosages, for longer duration and for additional indications including diabetic gastroparesis, the frequency of adverse events (apart from dry mouth) was considerably higher. This was particularly evident for pharmacologically predictable events related to increased prolactin. In addition to the reactions listed above, akathisia, breast discharge, breast enlargement, breast swelling, depression, hypersensitivity, lactation disorder, and irregular menstruation were also noted.

Omeprazole

The most common side effects (1-10% of patients) are headache, abdominal pain, constipation, diarrhoea, flatulence and nausea/vomiting.

SOC/frequency	Adverse reaction	
Blood and lymphatic system disorders		
Rare:	Leukopenia, thrombocytopenia	
Very rare:	Agranulocytosis, pancytopenia	
Immune system disorders		
Rare:	Hypersensitivity reactions e.g. fever, angioedema and anaphylactic	

SOC/frequency	Adverse reaction	
	reaction/shock	
Metabolism and nutrition disorders		
Rare:	Hyponatraemia	
Not known:	Hypomagnesaemia; severe hypomagnesaemia may result in hypocalcaemia. Hypomagnesaemia may also be associated with hypokalaemia.	
Psychiatric diso	rders	
Uncommon:	Insomnia	
Rare:	Agitation, confusion, depression	
Very rare:	Aggression, hallucinations	
Nervous system disorders		
Common:	Headache	
Uncommon:	Dizziness, paraesthesia, somnolence	
Rare:	Taste disturbance	
Eye disorders		
Rare:	Blurred vision	
Ear and labyrin	Ear and labyrinth disorders	
Uncommon:	Vertigo	
Respiratory, thoracic and mediastinal disorders		
Rare:	Bronchospasm	
Gastrointestinal disorders		
Common:	Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic	

SOC/frequency	Adverse reaction	
	gland polyps (benign)	
Rare:	Dry mouth, stomatitis, gastrointestinal candidiasis	
Not known:	Microscopic colitis	
Hepatobiliary disorders		
Uncommon:	Increased liver enzymes	
Rare:	Hepatitis with or without jaundice	
Very rare:	Hepatic failure, encephalopathy in patients with pre-existing liver disease	
Skin and subcutaneous tissue disorders		
Uncommon:	Dermatitis, pruritus, rash, urticaria	
Rare:	Alopecia, photosensitivity	
Very rare:	Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)	
Not known:	Subacute cutaneous lupus erythematosus	
Musculoskeletal	Musculoskeletal and connective tissue disorders	
Uncommon:	Fracture of the hip, wrist or spine	
Rare:	Arthralgia, myalgia	
Very rare:	Muscular weakness	
Renal and urinary disorders		
Rare:	Interstitial nephritis	
Not known:	Acute kidney injury	

SOC/frequency	Adverse reaction	
Reproductive system and breast disorders		
Very rare:	Gynaecomastia	
General disorders and administration site conditions		
Uncommon:	Malaise, peripheral oedema	
Rare:	Increased sweating	

Paediatric population

As per reported data, the safety of omeprazole has been assessed in a total of 310 children aged 0 to 16 years with acid-related disease. There are limited long-term safety data from 46 children who received maintenance therapy of omeprazole during a clinical study for severe erosive oesophagitis for up to 749 days. The adverse event profile was generally the same as for adults in short- as well as in long-term treatment. There are no long-term data regarding the effects of omeprazole treatment on puberty and growth.

Reporting adverse events

Report side effects directly via any point of contact of Torrent Pharma available at: <u>http://www.torrentpharma.com/Index.php/site/info/adverse_event_reporting</u>.

By reporting side effects, help us to provide more information on the safety of this medicine.

4.9 Overdose

Domperidone

Symptoms

Symptoms of over dosage may include agitation, altered consciousness, convulsions, disorientation, somnolence and extrapyramidal reactions.

Treatment

There is no specific antidote to domperidone, but in the event of overdose, standard symptomatic treatment should be given immediately. Gastric lavage as well as the administration of activated charcoal, may be useful. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Close medical supervision and supportive therapy is recommended.

Anticholinergic, anti-parkinson drugs may be helpful in controlling the extrapyramidal reactions.

Omeprazole

There is limited information available on the effects of overdoses of omeprazole in humans. In the literature, doses of up to 560 mg have been described, and occasional reports have been received when single oral doses have reached up to 2,400 mg omeprazole (120 times the usual recommended clinical dose). Nausea, vomiting, dizziness, abdominal pain, diarrhoea and

headache have been reported. Also apathy, depression and confusion have been described in single cases.

The symptoms described have been transient, and no serious outcome has been reported. The rate of elimination was unchanged (first order kinetics) with increased doses. Treatment, if needed, is symptomatic.

5. Pharmacological properties

5.1 Mechanism of Action

DOMSTAL O combines two drugs domperidone and omeprazole.

Domperidone

Domperidone is a dopamine antagonist with anti-emetic properties, Domperidone does not readily cross the blood-brain barrier. In domperidone users, especially in adults, extrapyramidal side effects are very rare, but domperidone promotes the release of prolactin from the pituitary. Its anti-emetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor trigger zone, which lies outside the blood-brain barrier in the area postrema. Animal studies, together with the low concentrations found in the brain, indicate a predominantly peripheral effect of domperidone on dopamine receptors.

Omeprazole

Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.

Omeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the intracellular canaliculi within the parietal cell, where it inhibits the enzyme H+ K+-ATPase - the acid pump. This effect on the final step of the gastric acid formation process is dose-dependent and provides for highly effective inhibition of both basal acid secretion and stimulated acid secretion, irrespective of stimulus.

5.2 Pharmacodynamic properties

Domperidone

Pharmacotherapeutic group: Propulsives, ATC code: A03FA03

Reported studies in man have shown oral domperidone to increase lower oesophaegeal pressure, improve antroduodenal motility and accelerate gastric emptying. There is no effect on gastric secretion.

Omeprazole

Pharmacotherapeutic group: Drugs for acid-related disorders, proton pump inhibitors, ATC code: A02BC01

Effect on gastric acid secretion

Oral dosing with omeprazole once daily provides for rapid and effective inhibition of daytime and night-time gastric acid secretion with maximum effect being achieved within 4 days of treatment. In a reported study, with omeprazole 20 mg, a mean decrease of at least 80% in 24-hour intragastric acidity is then maintained in duodenal ulcer patients, with the mean decrease in peak acid output after pentagastrin stimulation being about 70% 24 hours after dosing.

Oral dosing with omeprazole 20 mg maintains an intragastric pH of \ge 3 for a mean time of 17 hours of the 24-hour period in duodenal ulcer patients.

As a consequence of reduced acid secretion and intragastric acidity, omeprazole dosedependently reduces/normalizes acid exposure of the oesophagus in patients with gastrooesophageal reflux disease.

The inhibition of acid secretion is related to the area under the plasma concentration-time curve (AUC) of omeprazole and not to the actual plasma concentration at a given time.

No tachyphylaxis has been observed during treatment with omeprazole.

Other effects related to acid inhibition

During long-term treatment gastric glandular cysts have been reported in a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.

Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing drugs may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and, in hospitalised patients, possibly also Clostridium difficile.

During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.

An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients (both children and adults) during long term treatment with omeprazole. The findings are considered to be of no clinical significance.

Paediatric population

In a reported non-controlled study in children (1 to 16 years of age) with severe reflux oesophagitis, omeprazole at doses of 0.7 to 1.4 mg/kg improved oesophagitis level in 90% of the cases and significantly reduced reflux symptoms. In a single-blind study, children aged 0–24 months with clinically diagnosed gastro-oesophageal reflux disease were treated with 0.5, 1.0 or 1.5 mg omeprazole/kg. The frequency of vomiting/regurgitation episodes decreased by 50% after 8 weeks of treatment irrespective of the dose.

5.3 Pharmacokinetic properties

Domperidone

Absorption

Domperidone is rapidly absorbed after oral administration, with peak plasma concentrations occurring at approximately 1hr after dosing. The C_{max} and AUC values of domperidone

increased proportionally with dose in the 10 mg to 20 mg dose range. A 2- to 3-fold accumulation of domperidone AUC was observed with repeated four times daily (every 5 hr) dosing of domperidone for 4 days.

The low absolute bioavailability of oral domperidone (approximately 15%) is due to an extensive first-pass metabolism in the gut wall and liver. Although domperidone's bioavailability is enhanced in normal subjects when taken after a meal, patients with gastro-intestinal complaints should take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the absorption of domperidone. Oral bioavailability is decreased by prior concomitant administration of cimetidine and sodium bicarbonate. The time of peak absorption is slightly delayed and the AUC somewhat increased when the oral drug is taken after a meal.

Distribution

Oral domperidone does not appear to accumulate or induce its own metabolism; a peak plasma level after 90 minutes of 21 ng/ml after two weeks oral administration of 30 mg per day was almost the same as that of 18 ng/ml after the first dose. Domperidone is 91-93% bound to plasma proteins. Distribution studies with radiolabelled drug in animals have shown wide tissue distribution, but low brain concentration. Small amounts of drug cross the placenta in rats.

<u>Metabolism</u>

Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.

Excretion

Urinary and faecal excretions amount to 31 and 66% of the oral dose respectively. The proportion of the drug excreted unchanged is small (10% of faecal excretion and approximately 1% of urinary excretion). The plasma half-life after a single oral dose is 7-9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency.

Hepatic impairment

In subjects with moderate hepatic impairment (Pugh score 7 to 9, Child-Pugh rating B), the AUC and C_{max} of domperidone is 2.9- and 1.5-fold higher, respectively, than in healthy subjects. The unbound fraction is increased by 25%, and the terminal elimination half-life is prolonged from 15 to 23 hours. Subjects with mild hepatic impairment have a somewhat lower systemic exposure than healthy subjects based on C_{max} and AUC, with no change in protein binding or terminal half-life. Subjects with severe hepatic impairment were not studied. DOMSTAL O is contraindicated in patients with moderate or severe hepatic impairment (see section 4.3).

Renal impairment

In subjects with severe renal insufficiency (creatinine clearance <30ml/min/1.73m2) the elimination half-life of domperidone is increased from 7.4 to 20.8 hours, but plasma drug levels are lower than in healthy volunteers. Since very little unchanged drug (approximately 1%) is excreted via the kidneys, it is unlikely that the dose of a single administration needs to be adjusted in patients with renal insufficiency.

However, on repeated administration, the dosing frequency should be reduced to once or twice daily depending on the severity of the impairment, and the dose may need to be reduced.

Paediatric population

No pharmacokinetic data are available in the paediatric population.

Omeprazole

Absorption

Omeprazole and omeprazole magnesium are acid labile and are therefore administered orally as enteric-coated granules in capsules or tablets. Absorption of omeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. Absorption of omeprazole takes place in the small intestine and is usually completed within 3-6 hours. Concomitant intake of food has no influence on the bioavailability. The systemic availability (bioavailability) from a single oral dose of omeprazole is approximately 40%. After repeated once-daily administration, the bioavailability increases to about 60%.

Distribution

The apparent volume of distribution in healthy subjects is approximately 0.3 l/kg body weight. Omeprazole is 97% plasma protein bound.

Biotransformation

Omeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulfone. As a consequence of high affinity of omeprazole to CYP2C19, there is a potential for competitive inhibition and metabolic drug-drug interactions with other substrates for CYP2C19. However, due to low affinity to CYP3A4, omeprazole has no potential to inhibit the metabolism of other CYP3A4 substrates. In addition, omeprazole lacks an inhibitory effect on the main CYP enzymes.

Approximately 3% of the Caucasian population and 15-20% of Asian populations lack a functional CYP2C19 enzyme and are called poor metabolisers. In such individuals the metabolism of omeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 20 mg omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were also higher, by 3 to 5 times. These findings have no implications for the posology of omeprazole.

Elimination

The plasma elimination half-life of omeprazole is usually shorter than one hour both after single and repeated oral once-daily dosing. Omeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration. Almost 80% of an oral dose of omeprazole is excreted as metabolites in the urine, the remainder in the faeces, primarily originating from bile secretion.

Linearity/non-linearity

The AUC of omeprazole increases with repeated administration. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by omeprazole and/or its metabolites (e.g. the sulfone).

No metabolite has been found to have any effect on gastric acid secretion.

Special populations

Hepatic impairment

The metabolism of omeprazole in patients with liver dysfunction is impaired, resulting in an increased AUC. Omeprazole has not shown any tendency to accumulate with once daily dosing.

Renal impairment

The pharmacokinetics of omeprazole, including systemic bioavailability and elimination rate, are unchanged in patients with reduced renal function.

Elderly

The metabolism rate of omeprazole is somewhat reduced in elderly subjects (75-79 years of age).

Paediatric population

During treatment with the recommended doses to children from the age of 1 year, similar plasma concentrations were obtained as compared to adults. In children younger than 6 months, clearance of omeprazole is low due to low capacity to metabolise omeprazole.

6. Nonclinical properties

6.1 Animal Toxicology or Pharmacology

Domperidone

Reported electrophysiological in vitro and in vivo studies indicate an overall moderate risk of domperidone to prolong the QT interval in humans. In reported in vitro experiments on isolated cells transfected with hERG and on isolated guinea pig myocytes, exposure ratios ranged between 26- 47-fold, based on IC50 values inhibiting currents through IKr ion channels in comparison to the free plasma concentrations in humans after administration of the maximum daily dose of 10 mg administered 3 times a day. Safety margins for prolongation of action potential duration in in vitro experiments on isolated cardiac tissues exceeded the free plasma concentrations in humans at maximum daily dose (10 mg administered 3 times a day) by 45-fold. Safety margins in in vitro pro-arrhythmic models (isolated Langendorff perfused heart) exceeded the free plasma concentrations in humans at maximum daily dose (10 mg administered 3 times a day) by 9- up to 45-fold. In in vivo models the no effect levels for QTc prolongation in dogs and induction of arrhythmias in a rabbit model sensitized for torsade de pointes exceeded the free plasma concentrations in humans at maximum daily dose (10 mg administered 3 times a day) by more than 22-fold and 435-fold, respectively. In the anesthetized guinea pig model following slow intravenous infusions, there were no effects on QTc at total plasma concentrations of 45.4 ng/mL, which are 3-fold higher than the total plasma levels in humans at maximum daily dose

(10 mg administered 3 times a day). The relevance of the latter study for humans following exposure to orally administered domperidone is uncertain.

In the presence of inhibition of the metabolism via CYP3A4 free plasma concentrations of domperidone can rise up to 3-fold.


At a high, maternally toxic dose (more than 40 times the recommended human dose), teratogenic effects were seen in the rat. No teratogenicity was observed in mice and rabbits.

Omeprazole

Reportedly, gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with omeprazole. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition. Similar findings have been made after treatment with H2-receptor antagonists, proton pump inhibitors and after partial fundectomy. Thus, these changes are not from a direct effect of any individual active substance.

7. Description


Omeprazole is 5-methoxy-2[[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]sulfinyl]-1 Hbenzimidazole. having molecular formula of C17H19N3O3S molecular weight is 345.4 the chemical structure is:



Omeprazole is a white or almost white powder.

Domperidone:

Domperidone IS 5-Chloro-1-[1-[3-(2-oxo-2,3-dihydro1H-benzimidazol-1-ylpropyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2 –one having molecular formula C22H24CLN5O2 Molecular weight is 425.9 the chemical structure is:



Domperidone is a white or almost white powder. Soluble in *dimethylfonnamadie;* slightly soluble in *ethanol (95 per cent)* and in *methanol;* practically insoluble in *water*.

Light Violet/white hard gelatin capsules printed with "DOMSTAL- O" and Torrent logo (square emblem only) on the shells of the capsules, containing orange colored pellets and white to off-white pellets.

8. Pharmaceutical particulars

8.1 Incompatibilities

Not applicable

8.2 Shelf-life

Do not use later than the date of expiry

8.3 Packaging information

DOMSTAL O is packed in blister strips of 15 capsules.

8.4 Storage and handing instructions

Store at a temperature not exceeding 30°C. Protect from light and moisture.

9. Patient Counselling Information

DOMSTAL O

- Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 9.4.

What is in this leaflet

- 9.1. What DOMSTAL O is and what it is used for
- 9.2. What you need to know before you take DOMSTAL O
- 9.3. How to take DOMSTAL O
- 9.4. Possible side effects
- 9.5. How to store DOMSTAL O
- 9.6. Contents of the pack and other information

9.1 What DOMSTAL O is and what it is used for

DOMSTAL O contains domperidone and omeprazole. Domperidone belongs to a group of medicines called 'dopamine antagonists' and omeprazole belongs to a group of medicines called 'proton pump inhibitors'.

Domstal O is used for the treatment of Gastroesophageal Reflux Disease (GERD).

9.2. What you need to know before you take DOMSTAL O

Do not use DOMSTAL O:

- if you are allergic to domperidone, omeprazole, substituted benzimidazoles or any of the other ingredients of this medicine. If you think you may be allergic to any of these, talk to your doctor before taking DOMSTAL O
- Prolactin-releasing pituitary tumour (prolactinoma)
- if you have have a blockage or tear in your intestines, black, tarry bowel motions (stools) or notice blood in your bowel motions
- if you have liver disease.
- if you have underlying cardiac disorder or electrolyte disturbance
- with other drugs prolonging QT prolongation or CYP3A4 inhibitors/nelfinavir
- if you have a problem that gives you a low level of potassium or magnesium, or a high level of potassium in your blood.

Warnings and precautions

Before taking this medicine contact your doctor if:

- You suffer from liver problems (liver function impairment or failure)
- You suffer from kidney problems (kidney function impairment or failure). It is advisable to ask your doctor for advice in case of prolonged treatment as you may need to take a lower dose or take this medicine less often, and your doctor may want to examine you regularly.
- You are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking the medicine.
- DOMSTAL O may be associated with an increased risk of heart rhythm disorder and cardiac arrest. This risk may be more likely in those over 60 years old or taking higher doses. The risk also increases when DOMSTAL O is given together with some drugs. Tell your doctor or pharmacist if you are taking drugs to treat infection (fungal infections or bacterial infection) and/or if you have heart problems or AIDS/HIV.
- DOMSTAL O should be used at the lowest effective dose in adults and adolescents 12 years of age and older and a body weight of 35kg or more.
- While taking DOMSTAL O, contact your doctor if you experience heart rhythm disorders such as palpitations, trouble breathing and loss of consciousness. Treatment with Domstal O should be stopped.
- You lose a lot of weight for no reason and have problems swallowing.
- You get stomach pain or indigestion.
- You begin to vomit food or blood.
- You pass black stools (blood-stained faeces).

- You experience severe or persistent diarrhoea, as omeprazole has been associated with a small increase in infectious diarrhoea.
- You have severe liver problems.
- You have ever had a skin reaction after treatment with a medicine similar to omeprazole that reduces stomach acid.
- You are due to have a specific blood test (Chromogranin A).

If you take DOMSTAL O on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.

Taking a proton pump inhibitor like omeprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).

If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with DOMSTAL O. Remember to also mention any other ill-effects like pain in your joints.

Children and adolescents

Do not give this medicine to children under 1 year of age or < 10 kg.

Other medicines and DOMSTAL O

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines you can buy without a prescription, including herbal medicines. This is because DOMSTAL O can affect the way some other medicines work. Also, some medicines can affect the way DOMSTAL O works.

Do not take DOMSTAL O if you are taking medicine to treat:

- Fungal infections such as azole anti-fungals, specifically oral ketoconazole, fluconazole or voriconazole.
- Bacterial infections, specifically erythromycin, clarithromycin, telithromycin, moxifloxacin, pentamidine (these are antibiotics)
- Heart problems or high blood pressure (e.g., amiodarone, dronedarone, quinidine, disopyramide, dofetilide, sotalol, diltiazem, verapamil)
- Psychoses (e.g., haloperidol, pimozide, sertindole)
- Depression (e.g., citalopram, escitalopram)
- Gastro-intestinal disorders (e.g., cisapride, dolasetron, prucalopride)
- Allergy (e.g., mequitazine, mizolastine)
- Malaria (in particular halofantrine)
- AIDS/HIV (protease inhibitors)
- Cancer (e.g., toremifene, vandetanib, vincamine)

- nelfinavir (used to treat HIV infection)
- Digoxin (used to treat heart problems)
- Diazepam (used to treat anxiety, relax muscles or in epilepsy)
- Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking DOMSTAL O
- Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers. Your doctor may need to monitor you when you start or stop taking DOMSTAL O
- Rifampicin (used to treat tuberculosis)
- Atazanavir (used to treat HIV infection)
- Tacrolimus (in cases of organ transplantation)
- St John's wort (Hypericum perforatum) (used to treat mild depression)
- Cilostazol (used to treat intermittent claudication)
- Saquinavir (used to treat HIV infection)
- Clopidogrel (used to prevent blood clots (thrombi))
- Erlotinib (used to treat cancer)
- Methotrexate (a chemotherapy medicine used in high doses to treat cancer) if you are taking a high dose of methotrexate, your doctor may temporarily stop your DOMSTAL O treatment.

Tell your doctor or pharmacist if you are taking drugs to treat infection, heart problems or AIDS/HIV.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

DOMSTAL O is not likely to affect your ability to drive or use any tools or machines. Side effects such as dizziness and visual disturbances may occur. If affected, you should not drive or operate machinery.

DOMSTAL O capsules contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

9.3 How to take DOMSTAL O

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Your doctor will tell you how many capsules to take and how long to take them for. This will depend on your condition and how old you are.

When and how to take DOMSTAL O

Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is two capsules a day.

You should take this medicine for at least 2–3 consecutive days. Stop taking when you are completely symptom-free. You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with this medicine, but this medicine is not meant to bring immediate relief.

If you have no symptom-relief after taking this medicine for 2 weeks continuously, consult your doctor.

Take the capsule before a meal, at the same time every day.

You should swallow the capsule whole with some water.

Do not chew or break the capsule

If you take more DOMSTAL O than you should

If you take more DOMSTAL O than prescribed by your doctor, talk to your doctor or pharmacist straight away.

If you forget to take DOMSTAL O

If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.

9.4. Possible side effects

Stop taking DOMSTOL O immediately if:

- You get swelling of the hands, feet, ankles, face, lips or throat which may cause difficulty in swallowing or breathing. You could also notice an itchy, lumpy rash (hives) or nettle rash (urticaria). This may mean you are having an allergic reaction to DOMSTAL O.
- You notice any uncontrolled movements. These include irregular eye movements, unusual movements of the tongue, and abnormal posture such as a twisted neck, trembling and muscle stiffness. This is more likely to happen in children. These symptoms should stop once you stop taking DOMSTAL O.
- You have a very fast or unusual heartbeat. This could be a sign of a life-threatening heart problem.
- You have a fit (seizure).

Other side effects include:

Common (affects less than 1 in 10 people)

Headache

Effects on your stomach or gut: diarrhoea, stomach pain

Constipation, wind (flatulence)

Feeling sick (nausea) or being sick (vomiting)

Benign polyps in the stomach

Dry mouth

Uncommon side effects (may affect up to 1 in 100 people)

- Lowering of sexual drive (libido) in men
- Feeling anxious
- Feeling drowsy
- Itchy skin, rash
- Unusual production of breast milk in men and women
- Painful or tender breasts
- A general feeling of weakness
- Swelling of the feet and ankles
- Insomnia
- Dizziness
- Tingling feelings such as "pins and needles"
- Spinning feeling (vertigo)
- Changes in blood tests that check how the liver is working, lumpy rash (hives).

Rare side effects (may affect up to 1 in 1,000 people):

- Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.
- Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.
- Feeling agitated, confused or depressed.
- Taste changes.
- Eyesight problems such as blurred vision.
- Suddenly feeling wheezy or short of breath (bronchospasm).
- An inflammation of the inside of the mouth.
- An infection called "thrush" which can affect the gut and is caused by a fungus.
- Hair loss (alopecia).
- Joint pains (arthralgia) or muscle pains (myalgia).
- Severe kidney problems (interstitial nephritis).
- Increased sweating.

Very rare side effects (may affect up to 1 in 10,000 people):

- Changes in blood count including agranulocytosis (lack of white blood cells).
- Aggression.
- Seeing, feeling or hearing things that are not there (hallucinations).
- Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).
- Muscle weakness.
- Enlarged breasts in men.

Frequency not known:

- Inflammation in the gut (leading to diarrhoea).
- If you are on DOMSTOL O for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.
- Disorders of the cardiovascular system: heart rhythm disorders (rapid or irregular heart beat) have been reported; if this happens, you should stop the treatment immediately. DOMSTAL O may be associated with an increased risk of heart rhythm disorder and cardiac arrest. This risk may be more likely in those over 60 years old or taking higher doses. DOMSTAL O should be used at the lowest effective dose in adults and adolescents 12 years of age and older and a body weight of 35kg or more.
- Feeling agitated or irritable
- Kidney injury
- Feeling more nervous than usual
- Abnormal eye movements
- Inability to urinate
- In women, menstrual periods may be irregular or stop

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via any point of contact of Torrent Pharma available at: http://www.torrentpharma.com/Index.php/site/info/adverse_event_reporting.

By reporting side effects, you can help provide more information on the safety of this medicine.

9.5. How to store DOMSTAL O.

Store at a temperature not Exceeding 30°C, protected from light and moisture. Keep all capsules away from children.

9.6. Contents of the pack and other information

DOMSTAL O is packed in blister strips of 15 capsules.

Light Violet/white hard gelatin capsules printed with "DOMSTAL- O" and Torrent logo (square emblem only) on the shells of the capsules, containing orange colored pellets and white to off-white pellets.

DOMSTAL O contains domperidone and omeprazole.

The excipients used are hydroxy propyl methyl celu., magnesium stearate, ferric oxide yellow, ferric oxide red, talc, ethyl cellulose, methanol, methylene chloride.

10. Details of manufacturer

Torrent Pharmaceuticals Ltd

Vill.Bhud & Makhnu MAjra,

The.Baddi-173 205, Dist.Solan (H.P.), INDIA.

11. Details of permission or licence number with date

MNB/05/183 issued on 22.09.2010

12. Date of revision

June 2020

MARKETED BY



Torrent Pharmaceuticals Ltd.

IN/DOMSTAL O 10mg, 10mg/Jun-20/06/PI